Search Results 391-400 of 8841 for Conduction

  1. https://www.mayoclinic.org/arabic_procedure_concepts.xml

  2. Untitled

    Page 1. Page 2. Page 3.

  3. Endocrinology - Doctors - Mayo Clinic

    Endocrinology at Mayo Clinic offers treatment and specialty care for people with a wide range of rare and common endocrine disorders.

  4. https://www.mayoclinic.org/~/media/410DC08A1B274C6594A11A1F485AAACE

  5. https://www.mayoclinic.org/arabic_patient_consumer_faq.xml

  6. A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/​A011-16) - Mayo Clinic

    ... conduction defect (right bundle branch block; left bundle branch block; or interventricular conduction delay) is present * Personal or family history of ...

  7. A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients with Gastrointestinal Stromal Tumour After Progression with Imatinib - Mayo Clinic

    Patient with severe conduction disorders which are not prevented by permanent pacing (atrio-ventricular block 2 and 3, sino-atrial block); Syncope without ...

  8. A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility - Mayo Clinic

    ... conduction block > first degree, or acute myocardial ischemic condition suspected on the Electrocardiogram (ECG) at screening (e.g., ST-segment elevation ...

  9. Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study - Mayo Clinic

    (Correction of the actual QTc for the conduction defect of left bundle-branch can be made by subtracting the prolongation of the QRS due to the block from the ...

  10. Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer - Mayo Clinic

    Symptomatic congestive heart failure (i.e., Grade 2 or higher), history or current evidence of clinically significant cardiac arrhythmia and/or conduction ...